Press Room

Article / Sep 24, 2024

Formulating Inhaled Medicines

Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.

四色AV鈥檚 Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook

The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.听
To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook 鈥 鈥淭rends in Formulation鈥.听

In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.

Explore Eunice Costa鈥檚 full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.

听

Read the full article at听

Read the Trends in Formulation eBook at听

听

Also in the Press Room

See All

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
四色AV commitment to setting SBTs in line with the Paris Agreement

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of 四色AV麓s global expansion plans and marks a significant milestone in advancing 四色AV's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote 四色AV's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  鈥淭his strategic collaboration underscores 四色AV's dedication to delivering innovative solutions and exceptional service to its customers,鈥 said Yuken Kyoyama. 鈥淥ur partnership with Higuchi will help to show customers in Japan how 四色AV can meet their needs.鈥    Learn more about our business in Japan and visit our website hovione.co.jp    

News
四色AV proudly announces its collaborative venture with Higuchi.

四色AV forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Following the creation of offices in Shanghai and Beijing, 四色AV is pleased to announce the launch of its new website in Mandarin. This dedicated platform will enhance 四色AV麓s presence in China, offering tailored contents to better serve customers in this important market. The new site will provide comprehensive information about 四色AV麓s products and services, ensuring that Chinese clients have easier access to the innovative solutions and support that 四色AV is renowned for worldwide.   鈥淭he launch of the 四色AV Chinese website underscores our commitment to customers in China,鈥 said Ms. Jackie Liu, Country Head, China. 鈥淏y delivering localized content and support, we aim to foster stronger partnerships and drive mutual growth in this market. Our team of experts is fully committed to understanding and addressing our clients麓 unique challenges with agility and precision.鈥 Visit us at www.hovione.com.cn    

News
四色AV is closer to its customers with a new website in Mandarin

四色AV launches new website for the Chinese Market

Jun 14, 2024

Also in Events

See All